Author(s): Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS,
Abstract Share this page
Abstract In an effort to uncover systematic learnings that can be applied to improve compound survival, an analysis was performed on data from Phase II decisions for 44 programs at Pfizer. It was found that not only were the majority of failures caused by lack of efficacy but also that, in a large number of cases (43\%), it was not possible to conclude whether the mechanism had been tested adequately. A key finding was that an integrated understanding of the fundamental pharmacokinetic/pharmacodynamic principles of exposure at the site of action, target binding and expression of functional pharmacological activity (termed together as the 'three Pillars of survival') all determine the likelihood of candidate survival in Phase II trials and improve the chance of progression to Phase III. Copyright © 2012 Elsevier Ltd. All rights reserved.
This article was published in Drug Discov Today
and referenced in Journal of Proteomics & Bioinformatics